

# Incidence of Thyroid-Related Adverse Events in Melanoma Patients Treated with Pembrolizumab

Journal of Clinical Endocrinology and Metabolism

101, 4431-4439

DOI: [10.1210/jc.2016-2300](https://doi.org/10.1210/jc.2016-2300)

Citation Report

#	ARTICLE	IF	CITATIONS
1	New drugs, new toxicities: severe side effects of modern targeted and immunotherapy of cancer and their management. <i>Critical Care</i> , 2017, 21, 89.	2.5	340
2	Is autoimmunity the Achilles' heel of cancer immunotherapy?. <i>Nature Medicine</i> , 2017, 23, 540-547.	15.2	367
3	Pembrolizumab-Induced Thyroiditis: Comprehensive Clinical Review and Insights Into Underlying Involved Mechanisms. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 2770-2780.	1.8	210
4	Clinical Features of Nivolumab-Induced Thyroiditis: A Case Series Study. <i>Thyroid</i> , 2017, 27, 894-901.	2.4	123
5	Core Entrustable Professional Activities in Clinical Pharmacology for Entering Residency: Biologics. <i>Journal of Clinical Pharmacology</i> , 2017, 57, 947-955.	1.0	3
6	Pembrolizumab use for the treatment of advanced melanoma. <i>Expert Opinion on Biological Therapy</i> , 2017, 17, 765-780.	1.4	10
7	Thyroid abnormalities following the use of cytotoxic T-lymphocyte antigen-4 and programmed death receptor protein-1 inhibitors in the treatment of melanoma. <i>Clinical Endocrinology</i> , 2017, 86, 614-620.	1.2	165
8	Characterization of Thyroid Disorders in Patients Receiving Immune Checkpoint Inhibition Therapy. <i>Cancer Immunology Research</i> , 2017, 5, 1133-1140.	1.6	114
9	Endocrine toxicity of immune checkpoint inhibitors: essential crosstalk between endocrinologists and oncologists. <i>Cancer Medicine</i> , 2017, 6, 1923-1929.	1.3	39
10	Nuclear IRF-1 expression as a mechanism to assess "Capability" to express PD-L1 and response to PD-1 therapy in metastatic melanoma. , 2017, 5, 25.		35
11	Brain metastasis in a patient with melanoma receiving Pembrolizumab therapy. <i>Medicine (United States)</i> , 2017, 96, 107-110.	0.4	2
12	Polyendocrinopathy Resulting From Pembrolizumab in a Patient With a Malignant Melanoma. <i>Journal of the Endocrine Society</i> , 2017, 1, 646-649.	0.1	75
14	Rapid Evolution of Thyroid Dysfunction in Patients Treated with Nivolumab. <i>Endocrine Practice</i> , 2017, 23, 1223-1231.	1.1	23
15	Thyroid Autoimmunity: Role of Anti-thyroid Antibodies in Thyroid and Extra-Thyroidal Diseases. <i>Frontiers in Immunology</i> , 2017, 8, 521.	2.2	291
16	Safety and efficacy profile of pembrolizumab in solid cancer: pooled reanalysis based on randomized controlled trials. <i>Drug Design, Development and Therapy</i> , 2017, Volume 11, 2851-2860.	2.0	34
17	Thyroid dysfunctions secondary to cancer immunotherapy. <i>Journal of Endocrinological Investigation</i> , 2018, 41, 625-638.	1.8	59
18	Multimodality imaging of endocrine immune related adverse events: a primer for radiologists. <i>Clinical Imaging</i> , 2018, 50, 96-103.	0.8	23
19	Endocrine dysfunction induced by immune checkpoint inhibitors: Practical recommendations for diagnosis and clinical management. <i>Cancer</i> , 2018, 124, 1111-1121.	2.0	72

#	ARTICLE	IF	CITATIONS
20	<sup>18</sup> F-FDG PET/CT Can Predict Development of Thyroiditis Due to Immunotherapy for Lung Cancer. <i>Journal of Nuclear Medicine Technology</i> , 2018, 46, 260-264.	0.4	40
22	Patients With Antithyroid Antibodies Are Prone To Develop Destructive Thyroiditis by Nivolumab: A Prospective Study. <i>Journal of the Endocrine Society</i> , 2018, 2, 241-251.	0.1	146
23	Characterization and implications of thyroid dysfunction induced by immune checkpoint inhibitors in real-life clinical practice: a long-term prospective study from a referral institution. <i>Journal of Endocrinological Investigation</i> , 2018, 41, 549-556.	1.8	39
24	Endocrinopathies with use of cancer immunotherapies. <i>Clinical Endocrinology</i> , 2018, 88, 327-332.	1.2	20
25	Cancer immunotherapy-induced endocrinopathies: Clinical behavior and therapeutic approach. <i>European Journal of Internal Medicine</i> , 2018, 47, 6-13.	1.0	52
26	Development of thyroid dysfunction is associated with clinical response to PD-1 blockade treatment in patients with advanced non-small cell lung cancer. <i>Oncolmmunology</i> , 2018, 7, e1375642.	2.1	83
27	A Case of Aggravation of Thyroid Goiter after Treatment with PD-1 Inhibitor for Breast Cancer in Patients with Underlying Hashimoto's Thyroiditis. <i>International Journal of Thyroidology</i> , 2018, 11, 172.	0.1	0
28	Endocrine sequelae of immune checkpoint inhibitors. <i>Hormones</i> , 2018, 16, 341-350.	0.9	15
29	Predictive Factors of Nivolumab-induced Hypothyroidism in Patients with Non-small Cell Lung Cancer. <i>In Vivo</i> , 2018, 31, 1035-1039.	0.6	32
31	Nivolumab monotherapy or in combination with ipilimumab for metastatic melanoma: systematic review and meta-analysis of randomized-controlled trials. <i>Melanoma Research</i> , 2018, 28, 371-379.	0.6	15
32	Incidence of Thyroid Function Test Abnormalities in Patients Receiving Immune Checkpoint Inhibitors for Cancer Treatment. <i>Oncologist</i> , 2018, 23, 1236-1241.	1.9	20
33	Functional diagnostics for thyrotropin hormone receptor autoantibodies bioassays prevail over binding assays. <i>Frontiers in Bioscience - Landmark</i> , 2018, 23, 2028-2043.	3.0	17
34	Collateral Damage: Insulin-Dependent Diabetes Induced With Checkpoint Inhibitors. <i>Diabetes</i> , 2018, 67, 1471-1480.	0.3	386
35	The Current Understanding of the Endocrine Effects From Immune Checkpoint Inhibitors and Recommendations for Management. <i>JNCI Cancer Spectrum</i> , 2018, 2, pky021.	1.4	92
36	Nivolumab-induced thyroid dysfunction lacking antithyroid antibody is frequently evoked in Japanese patients with malignant melanoma. <i>BMC Endocrine Disorders</i> , 2018, 18, 36.	0.9	12
37	Thoracic Imaging of Solid Tumor Patients Treated with Immune Checkpoint Inhibitors. <i>Current Radiology Reports</i> , 2018, 6, 1.	0.4	1
38	Programmed cell death-1 and programmed cell death ligand-1 antibodies-induced dysthyroidism. <i>Endocrine Connections</i> , 2018, 7, R196-R211.	0.8	10
39	Immune-Related Thyroiditis with Immune Checkpoint Inhibitors. <i>Thyroid</i> , 2018, 28, 1243-1251.	2.4	160

#	ARTICLE	IF	CITATIONS
40	Expert opinion on thyroid complications in immunotherapy. <i>Annales D'Endocrinologie</i> , 2018, 79, 555-561.	0.6	33
41	Immune-Related Adverse Toxicities and Clinical Management. , 2018, , 577-589.		0
42	Clinical features of immune-related thyroid dysfunction and its association with outcomes in patients with advanced malignancies treated by PD-1 blockade. <i>Oncology Letters</i> , 2019, 18, 2140-2147.	0.8	35
43	The Immune Landscape of Thyroid Cancer in the Context of Immune Checkpoint Inhibition. <i>International Journal of Molecular Sciences</i> , 2019, 20, 3934.	1.8	69
45	Drug Effects on the Thyroid. <i>New England Journal of Medicine</i> , 2019, 381, 749-761.	13.9	98
46	Endocrine-related adverse events associated with immune-checkpoint inhibitors in patients with melanoma. <i>Cancer Medicine</i> , 2019, 8, 6585-6594.	1.3	31
47	Nivolumab Induced Thyroid Dysfunction: Unusual Clinical Presentation and Challenging Diagnosis. <i>Frontiers in Endocrinology</i> , 2018, 9, 813.	1.5	25
48	Tyrosine kinase inhibitors and immune checkpoint inhibitors-induced thyroid disorders. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 141, 23-35.	2.0	52
49	Pembrolizumab-Induced Thyroiditis. <i>Endocrine Pathology</i> , 2019, 30, 163-167.	5.2	28
50	Incidence, features, and prognosis of immune-related adverse events involving the thyroid gland induced by nivolumab. <i>PLoS ONE</i> , 2019, 14, e0216954.	1.1	92
51	The Impact of High-Dose Glucocorticoids on the Outcome of Immune-Checkpoint Inhibitor-Related Thyroid Disorders. <i>Cancer Immunology Research</i> , 2019, 7, 1214-1220.	1.6	44
52	Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 563-580.	12.5	1,235
53	Low frequency of positive antithyroid antibodies is observed in patients with thyroid dysfunction related to immune check point inhibitors. <i>Journal of Endocrinological Investigation</i> , 2019, 42, 1443-1450.	1.8	40
54	Baseline TSH Level is Associated with Risk of Anti-PD-1 Induced Thyroid Dysfunction. <i>Endocrine Practice</i> , 2019, 25, 824-829.	1.1	31
55	Incidence of thyroid dysfunctions during treatment with nivolumab for non-small cell lung cancer: Retrospective study of 105 patients. <i>Presse Medicale</i> , 2019, 48, e199-e207.	0.8	26
56	A Systematic Review and Meta-Analysis of Endocrine-Related Adverse Events Associated with Immune Checkpoint Inhibitors. <i>Hormone and Metabolic Research</i> , 2019, 51, 145-156.	0.7	234
57	Thyrotoxicosis: Diagnosis and Management. <i>Mayo Clinic Proceedings</i> , 2019, 94, 1048-1064.	1.4	52
58	Thyroid dysfunction induced by nivolumab: searching for disease patterns and outcomes. <i>Endocrine</i> , 2019, 64, 605-613.	1.1	46

#	ARTICLE	IF	CITATIONS
59	Toxicity of tumor immune checkpoint inhibitors—more attention should be paid. <i>Translational Lung Cancer Research</i> , 2019, 8, 1125-1133.	1.3	7
60	A Case Report of Graves™ Disease Induced by the Anti-Human Programmed Cell Death-1 Monoclonal Antibody Pembrolizumab in a Bladder Cancer Patient. <i>Case Reports in Endocrinology</i> , 2019, 2019, 1-5.	0.2	9
61	Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints. <i>Endocrine Reviews</i> , 2019, 40, 17-65.	8.9	349
62	Thyroiditis and immune check point inhibitors: the post-marketing experience using the French National Pharmacovigilance database. <i>Fundamental and Clinical Pharmacology</i> , 2019, 33, 241-249.	1.0	18
63	Adverse Events of Novel Therapies for Hematologic Malignancies: What Emergency Physicians Should Know. <i>Annals of Emergency Medicine</i> , 2020, 75, 264-286.	0.3	3
64	Thyroid Dysfunction, Recovery, and Prognosis in Melanoma Patients Treated with Immune Checkpoint Inhibitors: A Retrospective Review. <i>Endocrine Practice</i> , 2020, 26, 36-42.	1.1	20
66	Endocrine Complications. , 2020, , 707-714.e1.		0
67	PD-L1 Inhibitor-Induced Thyroiditis Is Associated with Better Overall Survival in Cancer Patients. <i>Thyroid</i> , 2020, 30, 177-184.	2.4	118
68	Thyroid disorders in programmed death 1 inhibitor-treated patients: Is previous therapy with tyrosine kinase inhibitors a predisposing factor?. <i>Clinical Endocrinology</i> , 2020, 92, 258-265.	1.2	18
69	Emergency management of immune-related toxicity. <i>Current Opinion in Oncology</i> , 2020, 32, 274-281.	1.1	5
70	Rational use of 18F-FDG PET/CT in patients with advanced cutaneous melanoma: A systematic review. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 153, 103044.	2.0	29
71	Immune Checkpoint Inhibitor-induced Thyroid Dysfunction Is Associated with Higher Body Mass Index. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e3620-e3627.	1.8	24
72	&lt;p&gt;Thyroid Dysfunctions Due to Immune Checkpoint Inhibitors: A Review&lt;/p&gt;. <i>International Journal of General Medicine</i> , 2020, Volume 13, 1003-1009.	0.8	21
73	Different patterns of treatment-related adverse events of programmed cell death-1 and its ligand-1 inhibitors in different cancer types: A meta-analysis and systemic review of clinical trials. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2020, 16, e160-e178.	0.7	6
74	Predictive Biomarkers of Immune Checkpoint Inhibitors-Related Toxicities. <i>Frontiers in Immunology</i> , 2020, 11, 2023.	2.2	50
75	Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune checkpoint inhibitor endocrinopathies and the role of advanced practice providers in the management of immune-mediated toxicities. <i>Supportive Care in Cancer</i> . 28. 6175-6181.	1.0	15
77	Diagnosis and management of immune-related adverse effects of immune checkpoint therapy in the emergency department. <i>Journal of the American College of Emergency Physicians Open</i> , 2020, 1, 1637-1659.	0.4	17
78	Endocrine Adverse Events of Nivolumab in Non-Small Cell Lung Cancer Patients—Literature Review. <i>Cancers</i> , 2020, 12, 2314.	1.7	13

#	ARTICLE	IF	CITATIONS
79	The biomarkers related to immune related adverse events caused by immune checkpoint inhibitors. <i>Journal of Experimental and Clinical Cancer Research</i> , 2020, 39, 284.	3.5	67
80	Immune Checkpoint Inhibitor-Induced Thyroiditis Is Associated with Increased Intrathyroidal T Lymphocyte Subpopulations. <i>Thyroid</i> , 2020, 30, 1440-1450.	2.4	53
81	Clinical Characteristics and Treatment of Immune-Related Adverse Events of Immune Checkpoint Inhibitors. <i>Immune Network</i> , 2020, 20, e9.	1.6	143
82	Endocrinopathies Associated with Immune Checkpoint Inhibitor Cancer Treatment: A Review. <i>Journal of Clinical Medicine</i> , 2020, 9, 2033.	1.0	13
83	Immune checkpoint inhibitor diabetes mellitus: a novel form of autoimmune diabetes. <i>Clinical and Experimental Immunology</i> , 2020, 200, 131-140.	1.1	104
84	Diagnosis and management of toxicities of immune checkpoint inhibitors in hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2020, 72, 320-341.	1.8	165
85	Simultaneous development of Gravesâ€™ disease and type 1 diabetes during anti-programmed cell death-1 therapy: A case report. <i>Journal of Diabetes Investigation</i> , 2020, 11, 1006-1009.	1.1	17
86	Anti-thyroid antibodies and thyroid echo pattern at baseline as risk factors for thyroid dysfunction induced by anti-programmed cell death-1 antibodies: a prospective study. <i>British Journal of Cancer</i> , 2020, 122, 771-777.	2.9	48
87	Thyroid Toxicity Following Immune Checkpoint Inhibitor Treatment in Advanced Cancer. <i>Thyroid</i> , 2020, 30, 1458-1469.	2.4	44
88	Clinical features and thyroid dysfunction in adverse events involving the pituitary gland during PD-1 blockade therapy. <i>Clinical Endocrinology</i> , 2021, 94, 258-268.	1.2	14
89	Increased thyroid uptake on 18F-FDG PET/CT is associated with the development of permanent hypothyroidism in stage IV melanoma patients treated with anti-PD-1 antibodies. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 679-687.	2.0	11
90	Autoimmune Endocrinopathies: An Emerging Complication of Immune Checkpoint Inhibitors. <i>Annual Review of Medicine</i> , 2021, 72, 313-330.	5.0	24
92	Immune checkpoint inhibitors-associated risk of immune-related hypothyroidism in older patients with advanced melanoma: a real-world analysis of US SEER-Medicare data. <i>Expert Opinion on Drug Safety</i> , 2021, 20, 489-497.	1.0	1
93	Toxicities of Novel Antineoplastic Therapies. , 2021, , 711-738.		1
94	The Role of Immunotherapy in the Treatment of Adrenocortical Carcinoma. <i>Biomedicines</i> , 2021, 9, 98.	1.4	8
95	18F-FDG PET-CT in Treatment Response Evaluation in Cutaneous Malignant Melanoma. , 2021, , 377-394.		0
96	How we treat endocrine complications of immune checkpoint inhibitors. <i>ESMO Open</i> , 2021, 6, 100011.	2.0	32
97	Thyroid function abnormality induced by PD-1 inhibitors have a positive impact on survival in patients with non-small cell lung cancer. <i>International Immunopharmacology</i> , 2021, 91, 107296.	1.7	20

#	ARTICLE	IF	CITATIONS
98	Higher baseline TSH levels predict early hypothyroidism during cancer immunotherapy. <i>Journal of Endocrinological Investigation</i> , 2021, 44, 1927-1933.	1.8	22
99	Thyroid Immune-related Adverse Events Following Immune Checkpoint Inhibitor Treatment. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e3704-e3713.	1.8	98
100	Gravesâ€™ Disease during Immune Checkpoint Inhibitor Therapy (A Case Series and Literature Review). <i>Cancers</i> , 2021, 13, 1944.	1.7	21
101	Adverse events induced by immune checkpoint inhibitors. <i>Current Opinion in Immunology</i> , 2021, 69, 29-38.	2.4	25
102	Endocrine-related adverse events in a large series of cancer patients treated with anti-PD1 therapy. <i>Endocrine</i> , 2021, 74, 172-179.	1.1	19
103	Prognostic impact of thyroid dysfunctions on progression-free survival in patients with metastatic melanoma treated with anti-PD-1 antibodies. <i>Melanoma Research</i> , 2021, 31, 208-217.	0.6	8
105	Pembrolizumab-induced hypothyroidism manifesting as myopathy and psychosis. <i>Melanoma Research</i> , 2021, 31, 405-406.	0.6	2
106	Thyroid dysfunction and survival in cancer patients treated with immune checkpoint inhibitors: analyses from a large single tertiary cancer center database. <i>Acta Oncologica</i> , 2021, 60, 1466-1471.	0.8	8
107	Hypothyroidism is a predictive factor of superior antitumour efficacy of programmed death 1 inhibitors in hepatocellular carcinoma. <i>International Journal of Cancer</i> , 2022, 150, 472-481.	2.3	8
108	Usage Patterns and Incidence of Thyroid-related Adverse Events in Patients Treated with PD-1 Inhibitors. <i>Korean Journal of Clinical Pharmacy</i> , 2021, 31, 188-197.	0.0	0
109	Endocrinopathies Associated With Immune Checkpoint Inhibitors. , 2022, , 301-314.		0
110	Thyroid dysfunction induced by immune checkpoint inhibitors is associated with a better progression-free survival and overall survival in non-small cell lung cancer: an original cohort study. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 2023-2033.	2.0	24
111	Baseline serum TSH levels predict the absence of thyroid dysfunction in cancer patients treated with immunotherapy. <i>Journal of Endocrinological Investigation</i> , 2021, 44, 1719-1726.	1.8	21
112	Immune checkpoint inhibitorâ€™associated hypercalcaemia. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 1598-1608.	0.4	12
113	Predicting response and toxicity to PD-1 inhibition using serum autoantibodies identified from immuno-mass spectrometry. <i>F1000Research</i> , 2020, 9, 337.	0.8	6
114	Two distinct clinical patterns of checkpoint inhibitor-induced thyroid dysfunction. <i>Endocrine Connections</i> , 2020, 9, 318-325.	0.8	23
115	Management of endocrine immune-related adverse events of immune checkpoint inhibitors: an updated review. <i>Endocrine Connections</i> , 2020, 9, R207-R228.	0.8	66
116	Immune checkpoint inhibitors and type 1 diabetes mellitus: a case report and systematic review. <i>European Journal of Endocrinology</i> , 2019, 181, 363-374.	1.9	154

#	ARTICLE	IF	CITATIONS
117	French Endocrine Society Guidance on endocrine side effects of immunotherapy. <i>Endocrine-Related Cancer</i> , 2019, 26, G1-G18.	1.6	95
118	Endocrine dysfunctions during treatment of immune-checkpoint inhibitors. <i>Trends in Immunotherapy</i> , 2018, 2, .	0.2	6
119	Incidence and Risk of Thyroid Dysfunction in Advanced or Metastatic Non-small Cell Lung Cancer Patients Treated with Pembrolizumab: A Meta-analysis. <i>Cureus</i> , 2019, 11, e5997.	0.2	5
120	Gestion des toxicités de l'immunothérapie. <i>Revue Des Maladies Respiratoires Actualites</i> , 2021, 13, 2S258-2S265.	0.0	0
121	Iperitroidismo. <i>EMC - AKOS - Trattato Di Medicina</i> , 2018, 20, 1-9.	0.0	0
122	Hipertroidismo. <i>EMC - Tratado De Medicina</i> , 2018, 22, 1-9.	0.0	0
123	Cancer Immunotherapy Related Endocrine Adverse Effects. <i>International Journal of Thyroidology</i> , 2019, 12, 97.	0.1	0
124	The Price of Success: Immune-Related Adverse Events from Immunotherapy in Lung Cancer. <i>Current Oncology</i> , 2021, 28, 4392-4407.	0.9	4
125	Assessment of TMB, PD-L1, and lymphocyte to monocyte ratio as predictive potential in a phase Ib study of sintilimab in patients with advanced solid tumors. <i>American Journal of Cancer Research</i> , 2021, 11, 4259-4276.	1.4	1
126	Immune-related Thyroid Dysfunction (irTD) in Non-small Cell Lung Cancer (NSCLC) Correlates With Response and Survival. <i>Cancer Diagnosis &amp; Prognosis</i> , 2022, 2, 55-63.	0.3	2
127	Endocrine Complications of Biological Cancer Therapies. , 2022, , 1775-1778.		0
128	Electrolyte and Acid-Base Disorders Associated with Cancer Immunotherapy. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2022, 17, 922-933.	2.2	15
129	Pembrolizumab and decitabine for refractory or relapsed acute myeloid leukemia. , 2022, 10, e003392.		34
130	Metabolic and Nutritional Disorders Following the Administration of Immune Checkpoint Inhibitors: A Pharmacovigilance Study. <i>Frontiers in Endocrinology</i> , 2021, 12, 809063.	1.5	0
131	Immune checkpoint inhibitors, endocrine adverse events, and outcomes of melanoma. <i>Endocrine Connections</i> , 2022, 11, .	0.8	4
133	Immune-Related Thyroid Adverse Events Predict Response to PD-1 Blockade in Patients with Melanoma. <i>Cancers</i> , 2022, 14, 1248.	1.7	3
134	Holistic Approach to Immune Checkpoint Inhibitor-Related Adverse Events. <i>Frontiers in Immunology</i> , 2022, 13, 804597.	2.2	27
135	Association between the type of thyroid dysfunction induced by immune checkpoint inhibitors and prognosis in cancer patients. <i>BMC Endocrine Disorders</i> , 2022, 22, 89.	0.9	14



#	ARTICLE	IF	CITATIONS
136	Immune checkpoint inhibitor-related thyroid dysfunction. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2022, 36, 101660.	2.2	24
137	The side effects of immune checkpoint inhibitor therapy on the endocrine system. <i>Indian Journal of Medical Research</i> , 2021, 154, 559.	0.4	7
138	Dynamic follow-up of the effects of programmed death 1 inhibitor treatment on thyroid function and sonographic features in patients with hepatocellular carcinoma. <i>Endocrine Connections</i> , 2022, 11, .	0.8	2
139	Human adipose-derived mesenchymal stem cells prevent type 1 diabetes induced by immune checkpoint blockade. <i>Diabetologia</i> , 2022, 65, 1185-1197.	2.9	19
140	Transcriptomic signatures associated with autoimmune thyroiditis in papillary thyroid carcinoma and cancer immunotherapy-induced thyroid dysfunction. <i>Computational and Structural Biotechnology Journal</i> , 2022, 20, 2391-2401.	1.9	0
141	Immune Checkpoint Inhibitor-induced Thyroid Disorders: A Single Center Experience. <i>Current Pharmaceutical Design</i> , 2023, 29, 295-299.	0.9	4
142	The role of PET/CT in thyroid autoimmune diseases. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 66, .	0.4	2
143	Steroid treatment in the management of destructive thyrotoxicosis induced by PD1 blockade. <i>European Thyroid Journal</i> , 2022, 11, .	1.2	2
144	Oncologic emergencies and urgencies: A comprehensive review. <i>Ca-A Cancer Journal for Clinicians</i> , 2022, 72, 570-593.	157.7	18
145	Elevated TSH Level, TgAb, and Prior Use of Ramucirumab or TKIs as Risk Factors for Thyroid Dysfunction in PD-L1 Blockade. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e4115-e4123.	1.8	6
146	Endocrine-related adverse conditions in patients receiving immune checkpoint inhibition: an ESE clinical practice guideline. <i>European Journal of Endocrinology</i> , 2022, 187, G1-G21.	1.9	35
147	Thyroid-related adverse events induced by immune checkpoint inhibitors. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	9
148	Thyroid autoantibodies. <i>Journal of Clinical Pathology</i> , 2023, 76, 19-28.	1.0	16
150	The influence of pharmaceutical care in patients with advanced non-small-cell lung cancer receiving combination cytotoxic chemotherapy and PD-1/PD-L1 inhibitors. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	0
151	Painless thyroiditis mimicking relapse of hyperthyroidism during or after potassium iodide or thionamide therapy for Gravesâ€™ disease resulting in remission. <i>Endocrine Journal</i> , 2023, 70, 207-222.	0.7	1
152	Delayed-onset immune-related adverse events involving the thyroid gland by immune checkpoint inhibitors in combination with chemotherapy: a case report and retrospective cohort study. <i>Endocrine Journal</i> , 2023, 70, 323-332.	0.7	3
153	Immunotherapy and Endocrine Oncology. , 2022, , 1-36.		0
154	Durvalumab-induced thyroiditis in a patient with non-small cell lung carcinoma: a case report and review of pathogenic mechanisms. <i>BMC Endocrine Disorders</i> , 2022, 22, .	0.9	3

#	ARTICLE	IF	CITATIONS
155	Hypothyroidism After Use of Immune Checkpoint Inhibitor Therapy in Patient With Graves' Disease: Cure?. , 2022, 1, .		1
156	Multiple Immunotherapy-Related Cardiovascular Sequelae. CJC Open, 2023, 5, 170-172.	0.7	1
157	Prognostic factors of toxicity of immune checkpoint inhibitors in nonsmall cell lung cancer and small cell lung cancer patients: The <scp>ToxImmune</scp> study. Cancer Reports, 2023, 6, .	0.6	2
158	Combined diabetic ketoacidosis and hyperosmolar hyperglycemic state in type 1 diabetes mellitus induced by immune checkpoint inhibitors: Underrecognized and underreported emergency in ICIs-DM. Frontiers in Endocrinology, 0, 13, .	1.5	1
159	Thyroid dysfunction in Chinese nasopharyngeal carcinoma after anti-PD-1 therapy and its association with treatment response. BMC Medicine, 2023, 21, .	2.3	0
160	Immune-Related Thyroiditis in Patients with Advanced Lung Cancer Treated with Immune Checkpoint Inhibitors: Imaging Features and Clinical Implications. Cancers, 2023, 15, 649.	1.7	1
161	Clinical outcomes of immune checkpoint inhibitor diabetes mellitus at a comprehensive cancer center. Immunotherapy, 2023, 15, 417-428.	1.0	0
162	A Rare Case of Pembrolizumab-Associated Gravesâ€™ Disease. Cureus, 2023, , .	0.2	1
163	Endocrine Consequences Following Immune Checkpoint Inhibitors Therapy. , 2023, , 1-32.		0
164	Diagnostic criteria and proposed management of immune-related endocrinopathies following immune checkpoint inhibitor therapy for cancer. Endocrine Connections, 2023, 12, .	0.8	3
165	Immune checkpoint inhibitor-related thyroid dysfunction. Annales D'Endocrinologie, 2023, 84, 346-350.	0.6	2
167	Correction of endocrine complications of oncoimmunotherapy. Obesity and Metabolism, 2023, 19, 418-430.	0.4	0
168	Permanent hypothyroidism following immune checkpoint inhibitors induced thyroiditis may be associated with improved survival: results of an explanatory study. Frontiers in Endocrinology, 0, 14, .	1.5	0
169	Risk of Thyroid Dysfunction in PD-1 Blockade Is Stratified by the Pattern of TgAb and TPOAb Positivity at Baseline. Journal of Clinical Endocrinology and Metabolism, 2023, 108, e1056-e1062.	1.8	4
171	Immune checkpoint biology in health & disease: Immune checkpoint biology and autoimmunity in cancer patients. International Review of Cell and Molecular Biology, 2024, , 181-206.	1.6	0
183	Cancer immunotherapy-associated endocrine complications and treatment strategies. , 2024, , 199-221.		0
184	Value of 2-[18F]FDG-PET/CT in identifying immune-related adverse events in patients with melanoma or non-small cell lung cancer: a systematic scoping review. Clinical and Translational Imaging, 2024, 12, 187-195.	1.1	0
185	Thyroid disorders induced by immune checkpoint inhibitors. Endocrine, 0, , .	1.1	0

#	ARTICLE	IF	CITATIONS
---	---------	----	-----------